“This has been a successful quarter for Immunovant. We delivered initial Phase 1 data for IMVT-1402, including initial data from the 300 mg MAD cohort ahead of schedule,” said Pete Salzmann, M.D., chief executive officer at Immunovant. “We look forward to sharing initial 600 mg MAD cohort data for IMVT-1402 later this month and proof-of-concept Phase 2 data for batoclimab in Graves’ disease by the end of the year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMVT:
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
- IMVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Immunovant management to meet virtually with Piper Sandler
- Immunovant price target raised to $57 from $28 at Piper Sandler
- Immunovant price target raised to $47 from $29 at H.C. Wainwright